Advertisement
With resistance expected from insurers, a lower price for evinacumab for homozygous familiar hypercholesterolemia (HoFH) is still a possibility.
Advertisement
Castaneda and Tundzhay comment: “Pushback, particularly from patients, due to an anticipated high coinsurance is also likely considering evinacumab may be used on top of other therapies they need to take.”
Inevitably, there will be patient assistance programs and evinacumab could be priced between the cost of Amgen’s Repatha and half that of Amryt Pharma’s Juxtapid, both approved in HoFH. Regeneron plans to submit an application to the US Food and Drug Administration in mid-2020.
Castaneda and Tundzhay noted: “In terms of competition, evinacumab may be preferred over Repatha but the latter also has cholesterol reduction benefit and more robust safety data that keeps it firmly in the treatment paradigm.”
Other companies with HoFH products in development include Novartis and LIB Therapeutics have Phase III trials; LipimetiX Development, AD Pharmaceuticals and RegenxBio have Phase II studies; and Innovent Biologics and Madrigal Pharmaceuticals have Phase I trials, according to GlobalData.
